Economic analyses to inform public health decision-making for tuberculosis: the role of understanding implementation
KeywordsTuberculosis Cost effectiveness Public health system
Tuberculosis (TB) kills more people than any other infectious disease in the world today . The global public health response is rising accordingly. To address the considerable gaps in TB management in high-burden countries, there is increasing pressure for health systems to rapidly and effectively implement innovations in TB diagnosis and treatment. High-level policy guidance, such as the World Health Organization’s End TB Strategy , the Sustainable Development Goals (SDG) , and the United Nation’s (UN’s) High Level Meeting in 2018  all call for novel strategies to optimize the impact of these interventions. Modeling analyses, such as that recently published by Sohn and colleagues in BMC Medicine, are becoming increasingly instrumental in guiding policy decisions .
However, in most high-burden settings, it remains unknown how best to operationalize and scale up interventions, at a sustainable cost – critical concerns of stakeholders and decision-makers. Research exists, but it makes for poor generalizations. Delivery models for effective implementation of TB diagnosis and treatment innovations are often context-specific – influenced by local conditions in health system capacity and demand for services. Effectiveness is often narrowly or inconsistently defined. Together, these limitations greatly reduce the utility of cost-effectiveness and budgetary impact analyses, which are intended to inform the choices that programs must make about how to scale up novel technologies to maximize public health benefit.
In their paper, Sohn and colleagues consider these extensive planning needs. The authors meticulously conceptualize and implement an epidemiologic and economic model to demonstrate how a national public health system, such as India’s Revised National Tuberculosis Programme (RNTCP), can design a cost-effective deployment of rapid point-of-care molecular diagnostic tests for TB (GeneXpert, GeneXpert MTB/RIF Cepheid, Sunnyvale, USA) . They describe three main drivers of cost-effectiveness for GeneXpert implementation: volume of testing, costs of sputum transportation in a decentralized approach, and the level of pre-treatment loss to follow-up for patients presenting to microscopy centers. These drivers are not unique to India; they have been described in a variety of high TB burden settings in both low- and middle-income countries [6, 7]. The strengths of this analysis are in its use of sensitivity and threshold analyses to characterize the factors that public health policymakers can consider or manipulate in designing an efficient approach to GeneXpert deployment. By applying context-specific cost and utilization assumptions, public health policymakers can reveal target conditions under which scale-up of GeneXpert would be cost-effective from a health system perspective (a major goal for economic analyses). But is this type of analysis sufficient, and how do policymakers know these costs for complex and under-used field activities?
Thus, challenges remain in comprehensive economic modeling of TB control. Drivers of GeneXpert cost-effectiveness, as described by Sohn and colleagues, notably depend on critical aspects of GeneXpert implementation and infrastructure. Human and capital costs related to infrastructure, capacity, and shared health systems resources, for example, are not routinely costed and, if mis-estimated, could skew results . Empirical implementation costs that reflect supporting services or activities – either existing, or that would be required to achieve optimal effect – are left unacknowledged. Using the example of a decentralized approach to GeneXpert, this type of cost would include the true cost of starting, scaling and maintaining a sputum transportation network. From a previous cost-effectiveness analysis of GeneXpert implementation in India, Sohn and colleagues provide credible estimates for costs; however, they also acknowledge the limited empirical implementation-based cost data that may affect their results . More broadly, economic evaluations also usually omit the perspectives of decision-makers such as patients, clinics, individual providers, and community organizations, for whom measures of effect are often different than traditional clinical efficacy. Cost drivers can also affect care participation, which will ultimately affect the fidelity of implementation and outcomes .
Novel measure of effectiveness
It is a critical and continuing challenge to enhance cost and cost-effectiveness analyses to reflect real-world implementation and its constraints in TB. Many analyses would be more powerful for use in public health decision-making if they could realistically integrate costs for implementation strategies that optimize effectiveness. While they are a move in the right direction, studies using more real-world TB outcomes, such as case detection rates and pre-treatment loss to follow-up, are still the exception . Additional outcomes of interest to stakeholders include those measuring integration, sustainability, and reach of novel interventions . For example, while GeneXpert economic analyses acknowledge that decentralized testing services may become less cost-effective as volume of testing decreases and infrastructure costs increase, they neglect the positive impact that such decentralization may have on improving reach, accessibility, and equity of TB services for at-risk or underserved populations. Is it possible to quantify these less traditional outcomes and cost the intervention components necessary to achieve them in a way that is meaningful to decision-makers? Perhaps more importantly, is there a way to integrate a more expansive interpretation of ‘effectiveness’ in a way that allows decision-makers to choose implementation strategies for novel interventions that may be less efficient than the cost-effectiveness optimal, but ultimately more successful?
In the future, innovative approaches to economic analyses that incorporate implementation factors will facilitate a more realistic and practical portrayal of the cost-effectiveness of TB innovations. This would provide a more actionable framework for public health decision-makers in programmatic and strategic planning to eliminate TB.
PBS and JGK conceived the manuscript. Both authors contributed to writing and editing the manuscript. Both authors read and approved the final manuscript.
PBS and JGK received funding from the US Centers for Disease Control and Prevention and the National Institutes of Health (PBS: K12 UCSF A129905–01; JGK MH107330). PBS is also funded by the Parker B Francis Foundation and the Swedish Research Council. The funders had no role in the in the conception, writing or editing of this manuscript. In addition, the viewpoints in this manuscript are those of the authors alone.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
- 1.World Health Organization (WHO). Global Tuberculosis Programme. In: Global Tuberculosis Report 2018. Geneva: WHO; 2018.Google Scholar
- 4.United Nations General Assembly. United to end tuberculosis: an urgent global response to a global epidemic. New York; 2018. https://www.un.org/pga/72/wp-content/uploads/sites/51/2018/09/Co-facilitators-Revised-text-Political-Declaraion-on-the-Fight-against-Tuberculosis.pdf. Accessed 11 Nov 2019
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.